Responding to COVID-19
In the face of this unprecedented pandemic, Gavi worked with countries to support COVID-19 response and to maintain and restore routine immunisation. The Alliance also co-lead global efforts on equitable access to COVID-19 vaccines.
Gavi's response
Respond and protect: With COVID-19 now reported in almost all Gavi-eligible countries, the Vaccine Alliance is providing immediate funding to health systems, enabling countries to protect health care workers, perform vital surveillance and training, and purchase diagnostic tests.
Maintain, restore and strengthen: Gavi will support countries to adapt and restart immunisation services, rebuild community trust and catch up those who have been missed both before and during the pandemic, while also investing in strengthening immunisation systems to be more resilient and responsive to the communities they serve.
Ensure global equitable access: Gavi is co-leading COVAX, the global effort to securing a global response to COVID-19 that is effective and fair, using its unique expertise to help identify and rapidly accelerate development, production and delivery of COVID-19 vaccines so that anyone that needs them, gets them.
WHO COVID-19 dashboard
COVID-19 vaccines
Accurate, evidence-based information about COVID-19 vaccines.
Situation reports
Historical updates concerning the impact of and response to the COVID-19 pandemic in Gavi-supported countries.
COVAX
Gavi co-lead COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involved coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.
Partner links
Key news
Scientists around the world are working faster than ever to develop and produce vaccines that can stop the spread of COVID-19, with 21 vaccines now being rolled out in countries worldwide. Here is an at-a-glance overview of those vaccines and…
Taking the long view on vaccine markets
Gavi’s long-term approach to developing healthy markets for critical vaccines has led to greater stability and security, providing countries with the confidence that supplies will be available to meet their demand.
2019 was a landmark year for countries co-financing their vaccine programmes
In 2019, a higher share of Gavi-supported countries than ever before met their co-financing obligations on time, thanks to strong political commitment.
COVID-19 explored
View allHow long after I get COVID-19 will I test negative?
Testing positive for COVID-19 – even without symptoms – can be disruptive to daily life, but how long should we expect to test positive for?
First published on 29 October 2021, updated on 13 September 2022
The COVAX Facility is seeking expressions of interest from the subject matter experts to join the COVAX Independent Product Group. The Independent Product Group (“IPG”) is established to provide scientific advice on COVID-19 vaccines and…
Q&A: Science ‘needs to listen to African voices’
Public speaking a lifelong skill for scientists. Drive behind research should come from grassroots. Science and art merge together in field of communication.
